Earnings History Data for Equillium (EQ) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Equillium

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
25-03-2024	AH		EQ	Equillium	97.00	-0.07	-0.17	0.00	Equillium GAAP EPS of -$0.07, revenue of $9.2M [3/25/2024 6:00 PM]	2.13	-0.31 (-12.70%)	2.30	-0.14 (-5.74%)	0.45 - 3.25	676,437	210,000	835
Equillium GAAP EPS of -$0.07, revenue of $9.2M [3/25/2024 6:00 PM]
08-11-2023	AH		EQ	Equillium	17.00	-0.11	-0.16	0.00	Equillium GAAP EPS of -$0.11 beats by $0.05, revenue of $8.87M beats by $4.12M [11/8/2023 5:32 PM]	0.48	-0.02 (-4.00%)	0.53	0.03 (6.00%)	0.47 - 1.97	144,320	80,000	22,327
Equillium GAAP EPS of -$0.11 beats by $0.05, revenue of $8.87M beats by $4.12M [11/8/2023 5:32 PM]
09-08-2023	AH		EQ	Equillium	28.00	-0.10	-0.19	0.00	Equillium GAAP EPS of -$0.10 beats by $0.06, revenue of $9.12M beats by $2.98M [8/9/2023 5:52 PM]	0.7919	0.02 (2.58%)	0.81	0.04 (4.82%)	0.48 - 3.20	66,334	720,000	1,533
Equillium GAAP EPS of -$0.10 beats by $0.06, revenue of $9.12M beats by $2.98M [8/9/2023 5:52 PM]
14-11-2022	PM		EQ	Equillium	58.00	-0.40	-0.39	0.00	Equillium GAAP EPS of -$0.40 misses by $0.02 [11/15/2022 6:36 AM]	1.82	0.10 (5.81%)	0.0	0.0 (0.00%)	1.56 - 5.68	20,311	20,000	0
Equillium GAAP EPS of -$0.40 misses by $0.02 [11/15/2022 6:36 AM] Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates [Nov-14-22 04:01PM] Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022 [Nov-14-22 08:00AM]
15-08-2022	AH		EQ	Equillium	94.00	-0.41	-0.40	0.00	Equillium GAAP EPS of -$0.41 in-line [8/15/2022 5:51 PM]	2.95	0.05 (1.79%)	2.70	-0.12 (-4.26%)	1.66 - 7.12	40,104	20,000	100
Equillium GAAP EPS of -$0.41 in-line [8/15/2022 5:51 PM] Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates [Aug-15-22 04:01PM]
10-11-2021	AH		EQ	Equillium, Inc.	194.51	-0.35	-0.34	-0.31	Equillium EPS misses by $0.01 [11/10/2021 4:58 PM]	5.66	-0.56 (-9.00%)	6.10	-0.12 (-1.93%)	3.53 - 11.33	105,539	50,000	1,200
Equillium EPS misses by $0.01 [11/10/2021 4:58 PM] Equillium to Present at Two Upcoming Investor Conferences [Nov-09-21 08:00AM]
10-08-2021	AH	4:00 PM ET (Aug 10)	EQ	Equillium, Inc.	175.00	-0.31	-0.31	0.00	Equillium EPS beats by $0.01 [8/10/2021 4:50 PM]	6.15	0.06 (0.99%)	6.08	-0.01 (-0.16%)	3.47 - 12.29	338,762	60,000	119
Equillium EPS beats by $0.01 [8/10/2021 4:50 PM] Equillium amends early-stage trial of itolizumab for autoimmune disease [8/11/2021 4:21 PM] Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update [Aug-10-21 04:01PM] Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis [Aug-11-21 04:00PM]
13-05-2021	AH	4:05 PM ET (May 13)	EQ	Equillium, Inc.	175.11	-0.33	-0.34	-0.45	Equillium EPS beats by $0.01 [5/13/2021 5:19 PM]	5.40	0.15 (2.86%)	5.20	-0.05 (-0.95%)	2.53 - 27.05	89,690	150,000	307
Equillium EPS beats by $0.01 [5/13/2021 5:19 PM] Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association [May-13-21 08:00AM] Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update [May-13-21 04:02PM]
24-03-2021	AH		EQ	Equillium, Inc.	239.29	-0.36	-0.38	-0.44	Equillium EPS beats by $0.02 [3/24/2021 4:50 PM]	6.98	0.09 (1.31%)	6.81	-0.08 (-1.16%)	2.30 - 27.05	216,974	180,000	704
Equillium EPS beats by $0.02 [3/24/2021 4:50 PM] Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update [Mar-24-21 04:05PM]
10-11-2020	AH		EQ	Equillium, Inc.	118.65	-0.31	-0.41	-0.35	Equillium EPS beats by $0.09 [11/10/2020 4:35 PM]	5.08	1.60 (45.98%)	3.54	0.06 (1.72%)	2.20 - 27.05	35,949,803	2,752,117	6,978